A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib

BACKGROUND: Targeted therapy has revolutionized the treatment of patients with malignancies harboring mutations in driver genes and has brought a favorable survival benefit to the population with actionable oncogenic mutations. In recent years, the MET exon14 skipping mutation has been recognized as...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yan, Jiang, Bo, He, Yuange, Zhang, Chu, Zhou, Wenjie, Fang, Cheng, Gu, Dejian, Zhang, Minxia, Ji, Mei, Shi, Juntao, Yang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229853/
https://www.ncbi.nlm.nih.gov/pubmed/35739536
http://dx.doi.org/10.1186/s12920-022-01291-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229853/
https://www.ncbi.nlm.nih.gov/pubmed/35739536
http://dx.doi.org/10.1186/s12920-022-01291-z

Ejemplares similares